ArticleCancer research2017
Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy.
Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 102 citations in OpenAlex.
- Trial
- Armed Oncolytic Myxoma Virus Induces Systemic Antitumor Immunity Against Solid Tumors in Immunocompetent Mice.Research square · 2026Article
- Oncolytic virus with an immune stimulatory payload for osteosarcoma therapy.Cancer immunology, immunotherapy : CII · 2026Article
- Cracking the shield: oncolytic viruses versus the tumor-immune fortress.Cancer cell international · 2026Review
- Immune modulatory oncolytic virus for osteosarcoma therapy.Research square · 2026Article
- Intratumoral PD-1-directed IL-2 expression via oncolytic vaccinia virus elicits superior antitumor effects with enhanced safety.Journal for immunotherapy of cancer · 2026Article
- Myeloid-derived suppressor cells inhibit the replication of oncolytic virus by reducing intratumoral arginine levels.Molecular therapy. Oncology · 2025Article
- Novel oncolytic adenovirus-based PEPvIII vaccine displays a super antitumor effect in glioma models.Journal for immunotherapy of cancer · 2025Article
- Constructing the cure: engineering the next wave of antibody and cellular immune therapies.Journal for immunotherapy of cancer · 2025Review
- Article
- Comparison of the L3-23K and L5-Fiber Regions for Arming the Oncolytic Adenovirus Ad5-Delta-24-RGD with Reporter and Therapeutic Transgenes.International journal of molecular sciences · 2025Article
- Investigating the potential of oncolytic viruses in the treatment of melanoma: where do we go from here?Skin health and disease · 2025Review
- IL-12-mediated toxicity from localized oncolytic virotherapy can be reduced using systemic TNF blockade.Molecular therapy. Oncology · 2024Article
- A Virus-Inspired Inhalable Liponanogel Induces Potent Antitumor Immunity and Regression in Metastatic Lung Tumors.Cancer research · 2024Article
- OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions.International journal of molecular sciences · 2024Review
- Article
- Research progress and application of single-cell sequencing in head and neck malignant tumors.Cancer gene therapy · 2024Review
- A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon.Molecular therapy oncolytics · 2023Review
- Reversing T Cell Exhaustion by Converting Membrane PD-1 to Its Soluble form in Jurkat Cells; Applying The CRISPR/Cas9 Exon Skipping Strategy.Cell journal · 2023Article
- Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?Journal for immunotherapy of cancer · 2023Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Oncolytic virotherapy represents an attractive option for the treatment of a variety of aggressive or refractory tumors. While this therapy is effective at rapidly debulking directly injected tumor masses, achieving complete eradication of established disease has proven difficult. One method to overcome this challenge is to use oncolytic viruses to induce secondary antitumor immune responses. Unfortunately, while the initial induction of these immune responses is typically robust, their subsequent efficacy is often inhibited through a variety of immunoregulatory mechanisms, including the PD1/PDL1 T-cell checkpoint pathway. To overcome this inhibition, we generated a novel recombinant myxoma virus (vPD1), which inhibits the PD1/PDL1 pathway specifically within the tumor microenvironment by secreting a soluble form of PD1 from infected cells. This virus both induced and maintained antitumor CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.